---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-008654"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2026-08-12T12:30:57+00:00"
generated_at: "2026-08-12T12:35:06.336816+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# NeOnc NEO100 Phase 2a meets primary endpoint: PFS-6 48.9% vs 20% benchmark

## Summary
- PFS-6 48.9% (95% CI 26.3-68.1) vs 20% SOC benchmark, p=0.0047; median PFS 3.91 mo.
- Median OS 26.09 months; OS rates 86.7% at 6 mo, 60.9% at 12 mo, 54.1% at 24 mo.
- 5 of 24 patients remain on treatment; one progression-free ~19 mo, one partial response 114 days; ORR 8.3%.
- No major toxicities; adverse events predominantly low-grade; self-administered intranasally at home.
- Company to request Type B FDA meeting to align on registrational path; full data at future medical meeting.

## SEC filing metadata
- accession: 0001829126-26-008654
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2026-08-12T12:30:57+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912626008654/0001829126-26-008654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912626008654/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-008654
- JSON: https://secwatch.observer/filing/0001829126-26-008654.json
- Plain text: https://secwatch.observer/filing/0001829126-26-008654.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.